MedTrace Logo

Pharmacokinetic and Pharmacodynamic Effects of MTR107 in End-Stage Renal Disease (ESRD) Patients

NCT00448071 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2007-03-15

No results posted yet for this study

Summary

MTR107 effect on blood pressure throught the dialysis procedure and its ability to prevent Intra dialytic Hypotension

Conditions

Interventions

DRUG

MTR107

Sponsors & Collaborators

  • Meditor Pharmaceuticals Ltd.

    collaborator INDUSTRY

  • Wolfson Medical Center

    lead OTHER_GOV

Principal Investigators

  • Zeev Katzir, MD · Wolfson Medical Center

  • Shay Efrati, MD · Asaf Harofeh Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Completion
2007-03-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00448071 on ClinicalTrials.gov